IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImageneBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.00−0.04 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $64.65M
- P/E (TTM)
- –
- Dividend yield
- –
ImageneBio, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -7370.1%
- Net margin
- -6560.5%
- Return on equity, FY2025
- 330.7%
Financial strength
- Current ratio
- 21.47
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1440.4%
Valuation
- P/E ratio
- –
- Price to sales
- 80.81
- Price to book
- 0.46
- Dividend yield
- –